Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net.

IF 12.9 1区医学 Q1 HEMATOLOGY

Blood Cancer Journal Pub Date : 2025-07-03 DOI:10.1038/s41408-025-01324-7

Minoru Kanaya, Masahiro Onozawa, Toshihiro Matsukawa, Naoki Miyashita, Fumiaki Fujii, Shota Yoshida, Jun Nagai, Masayuki Aiba, Daisuke Hidaka, Junichi Hashiguchi, Hajime Senjo, Tetsuyuki Igarashi, Masahiro Chiba, Satoshi Yamamoto, Taku Shimizu, Takashi Ishio, Shota Yokoyama, Ko Ebata, Satoshi Iyama, Tatsuo Oyake, Takeshi Kondo, Takanori Teshima

引用次数: 0

Abstract Image

查看原文本刊更多论文

未经治疗的急性髓性白血病患者在阿扎胞苷-venetoclax第一个周期中使用14天、21天或标准28天venetoclax的可比结果：来自北海道白血病网的真实世界经验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Journal ONCOLOGY-

CiteScore

16.70

自引率

2.30%

发文量

153

审稿时长

>12 weeks

期刊介绍： Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as: Preclinical studies of new compounds, especially those that provide mechanistic insights Clinical trials and observations Reviews related to new drugs and current management of hematologic malignancies Novel observations related to new mutations, molecular pathways, and tumor genomics Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.